Pyrazolformyl piperazinone compound, pharmaceutical composition and use thereof

By developing the highly selective binding of pyrazolecarboxylpiperazine ketone compounds with BMPR1B, the lack of existing TGF-β signaling pathway inhibitors in tumor cell lethality is solved, and effective treatment of a variety of cancers has been achieved.

WO2024239186A1PCT designated stage expired Publication Date: 2024-11-28IREGENE THERAPEUTICS LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/095443
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-22
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

The existing TGF-β signaling pathway inhibitors are limited in their lethality to tumor cells and the types of kinases that selectively inhibit, making it difficult to effectively treat a variety of high-incidence diseases, especially cancer.

Method used

A pyrazolecarboxylpiperazine compound was developed to form a stable complex through high selective binding with BMPR1B, thereby achieving inhibition of BMPR1B and having higher tumor cell lethality.

Benefits of technology

Compared with existing small molecule inhibitors, such as LY2157299, pyrazolecarboxylpiperazine ketones have higher lethality against tumor cells, showing effective therapeutic potential in a variety of cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023095443_28112024_PF_FP_ABST
    Figure CN2023095443_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to the technical field of medicines, in particular to a pyrazolformyl piperazinone compound, a pharmaceutical composition and the use thereof. The pyrazolformyl piperazinone compound has a structure as shown in formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotopic label, isomer or prodrug of the structure as shown in formula I.
Need to check novelty before this filing date? Find Prior Art

Description

Pyrazolecarbonylpiperazinones, pharmaceutical compositions and applications thereof Technical Field

[0001] The present application relates to the field of medical technology, and in particular to a pyrazolecarbonylpiperazinone compound, a pharmaceutical composition and applications thereof. Background Art

[0002] Transforming growth factor-β (TGF-β), a member of the TGF-β superfamily, plays a crucial role in regulating cell growth and differentiation. Dysfunction of the TGF-β signaling pathway is associated with human diseases, including cancer, fibrosis, systemic sclerosis, and genetic disorders (Wakefield LM and Hill CS. Nat Rev Cancer 2013, 13:328–341). For example, in advanced cancers, TGF-β often promotes tumor progression and metastasis, acting as a carcinogen (Massagué. J. Cell. 2008, 134:215–230).

[0003] There are two main types of TGF-β cell membrane receptors: TGF-β type I receptors and TGF-β type II receptors. In vertebrates, there are seven known type I receptors (activin receptor-like kinases): ALK1 (ACVRL1), ALK2 (ACVR1), ALK3 (BMPR1A), ALK4 (ACVR1B), ALK5 (TGFBR1), ALK6 (BMPR1B), and ALK7 (ACVR1C); and five type II receptors: TGFβRⅡ, ACTRⅡ, ACTRⅡB, BMPRⅡ, and AMHRⅡ. Among them, the ALK6 gene, also known as the BMPR1B (bone morphogenetic protein receptor, type IB) gene, belonging to the type I receptor, has been found to be associated with a variety of high-risk diseases, such as breast cancer, gastric cancer, and pulmonary arterial hypertension. Therefore, how to artificially inhibit BMPR1B to achieve the treatment of related diseases is a hot issue that needs to be solved urgently in the medical field.

[0004] Summary of the Invention

[0005] Based on this, it is necessary to provide a pyrazole-based piperazinone compound that can highly selectively inhibit BMPR1B, has anti-tumor activity, and is expected to be used in the clinical treatment of cancer.

[0006] In a first aspect of the present application, a pyrazole-1-piperazinone compound is provided, wherein the pyrazole-1-piperazinone compound has a structure represented by Formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled compound, isomer, or prodrug of the structure represented by Formula I;

[0007] Wherein, ring A is selected from any of the following structures:

[0008] Y is -(CH2) n -, n is 0, 1, 2 or 3;

[0009] R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1~C6 alkyl, C1~C6 alkoxy, C6~C 10 Aryl or C3~C 10 heteroaryl;

[0010] R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy;

[0011] “*” indicates the attachment site.

[0012] In a second aspect of the present application, a pharmaceutical composition is provided, comprising the aforementioned pyrazolecarbonylpiperazinone compound and at least one pharmaceutically acceptable carrier.

[0013] The third aspect of the present application provides the use of the aforementioned pyrazole carbonyl piperazinone compound or the aforementioned pharmaceutical composition in the preparation of a medicament for treating one or more of the following diseases: cancer, pulmonary hypertension.

[0014] The fourth aspect of the present application provides the use of the aforementioned pyrazole carbonyl piperazinone compounds as BMPR1B inhibitors.

[0015] In a fifth aspect of the present application, a method for inhibiting BMPR1B expression is provided, comprising the following steps:

[0016] The aforementioned pyrazole-based piperazinone compound is contacted with cells, biological tissues or organoids containing BMPR1B.

[0017] The sixth aspect of the present application provides a method for treating cancer or pulmonary hypertension, comprising the following steps: administering to the patient a therapeutically effective amount of the aforementioned pyrazolecarbonylpiperazinone compound, or administering to the patient a therapeutically effective amount of the aforementioned pharmaceutical composition. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 shows the specificity of pyrazole-based piperazinone compounds binding to their targets based on kinase activity screening; Figure 1A shows the effect analysis of compound II-1 on the enzymatic activity of 330 kinases; Figures 1B and 1C show the kinase activity test results of compound II-1 at different concentrations against TGFBR1 and BMPR2;

[0019] Figure 2 shows information on the interaction between compounds and BMPR1B in the pyrazole-piperazinone compound-BMPR1B complex displayed by PyMol software; wherein the compound in Figure 2A is II-13, the compound in Figure 2B is II-11, the compound in Figure 2C is II-2, and the compound in Figure 2D is II-1;

[0020] FIG3 shows the results of the tumor cell killing experiment of compound II-1 and LY2157299. DETAILED DESCRIPTION

[0021] To facilitate understanding of the present application, a more comprehensive description of the present application will be provided below with reference to the accompanying drawings. The accompanying drawings illustrate preferred embodiments of the present application. However, the present application may be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a more thorough and comprehensive understanding of the disclosure of the present application.

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing specific embodiments only and are not intended to limit this application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0023] In this application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0024] In this application, when referring to numerical ranges, unless otherwise specified, the numerical ranges are considered continuous and include the minimum and maximum values ​​of the range, as well as every value between such minimum and maximum values. Further, when a range refers to an integer, every integer between the minimum and maximum values ​​of the range is included. In addition, when multiple ranges are provided to describe a feature or characteristic, the ranges can be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges subsumed therein.

[0025] Unless otherwise specified, the percentage contents mentioned in this application refer to mass percentage for solid-liquid mixture and solid-solid mixture, and refer to volume percentage for liquid-liquid mixture.

[0026] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.

[0027] The temperature parameters in this application, unless otherwise specified, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows for temperature fluctuations within the precision range of instrument control.

[0028] Explanation of terms

[0029] The term "alkyl" refers to a monovalent residue formed by the loss of a hydrogen atom from a saturated hydrocarbon containing primary (normal) carbon atoms, secondary carbon atoms, tertiary carbon atoms, quaternary carbon atoms, or combinations thereof. Phrases containing this term, such as "C1-C6 alkyl," refer to an alkyl group containing 1 to 6 carbon atoms, and each occurrence may independently be a C1 alkyl, C2 alkyl, C3 alkyl, C4 alkyl, C5 alkyl, or C6 alkyl group. Suitable examples include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), 1-propyl (n-Pr, n-propyl, -CH2CH2CH3), 2-propyl (i-Pr, i-propyl, -CH(CH3)2), 1-butyl (n-Bu, n-butyl, -CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, -CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, -CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH3)3), 1-pentyl (n-pentyl, -CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH (CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2) and 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3.

[0030] The term "alkoxy" refers to a group having the structure -O-alkyl, i.e., an alkyl group as defined above attached to the adjacent group via an oxygen atom. Phrases containing this term, for example, "C1-C6 alkoxy" means that the alkyl portion contains 1 to 6 carbon atoms, and each occurrence can be independently C1 alkoxy, C4 alkoxy, C5 alkoxy, or C6 alkoxy. Suitable examples include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-O-CH2CH3 or -OEt), and tert-butoxy (-OC(CH3)3 or -OtBu).

[0031] "Aryl" refers to an aromatic hydrocarbon group derived from an aromatic ring compound by removing a hydrogen atom. It can be a monocyclic aromatic group, a condensed aromatic group, or a polycyclic aromatic group. For polycyclic aromatic groups, at least one of them is an aromatic ring system. For example, "C6-C 10 "Aryl" refers to an aromatic group containing 6 to 10 carbon atoms, each occurrence of which can be independently C6 aryl, C7 aryl, C8 aryl, C9 aryl or C 10 Suitable examples include, but are not limited to, benzene, biphenyl, naphthalene, and their derivatives.

[0032] "Heteroaryl" means that at least one carbon atom in an aryl or cyclopentadienyl group is replaced by a non-carbon atom, which may be a nitrogen atom, an oxygen atom, or a sulfur atom. For example, "C3-C 10 The term "heteroaryl" refers to a heteroaryl group containing 3 to 10 carbon atoms, which, at each occurrence, is independently C3 heteroaryl, C4 heteroaryl, C5 heteroaryl, C6 heteroaryl, C7 heteroaryl or C8 heteroaryl. Suitable examples include, but are not limited to, furan, benzofuran, thiophene, benzothiophene, pyrrole, pyrazole, triazole, imidazole, oxazole, oxadiazole, thiazole, tetrazole, indole, carbazole, pyrroloimidazole, pyrrolopyrrole, thienopyrrole, thienothiophene, furopyrrole, furofuran, thienofuran, benzisoxazole, benzisothiazole, benzimidazole, pyridine, pyrazine, pyridazine, pyrimidine, triazine, quinoline, isoquinoline, o-naphthyridine, quinoxaline, phenanthridine, primidine, quinazoline and quinazolinone.

[0033] As used herein, "prodrug" refers to any compound that, when administered to an organism, produces a drug, i.e., an active ingredient, as a result of a spontaneous chemical reaction, an enzyme-catalyzed chemical reaction, photolysis, and / or metabolic chemical reaction. Prodrugs are therefore covalently modified analogs or latent forms of therapeutically active compounds. Suitable examples include, but are not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amide, carbamate, azo compound, phosphoramide, glucoside, ether, acetal, and the like forms of the compound.

[0034] "Pharmaceutically acceptable" refers to those ligands, materials, compositions, and / or dosage forms that are suitable for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0035] A "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. As used herein, the language "pharmaceutically acceptable carrier" includes buffers, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with drug administration. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients in the formulation and not harmful to the patient. Suitable examples include, but are not limited to: (1) sugars such as lactose, glucose, and sucrose; (2) starches such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrins; (3) cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, and maltose. Rice oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer; and (21) other nontoxic compatible substances used in pharmaceutical formulations.

[0036] "Pharmaceutically acceptable salt" refers to a salt suitable for use as a drug formed by any compound of the structure shown with an acid or base. Pharmaceutically acceptable salts include inorganic salts and organic salts. Among them, one type of salt is a salt formed by the compound of the present application with an acid. Acids suitable for forming salts include but are not limited to: inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid. Another type of salt is a salt formed by a compound of the present invention and a base. Suitable bases for forming salts include, but are not limited to, alkali metal salts (e.g., sodium salts or potassium salts), alkaline earth metal salts (e.g., magnesium salts or calcium salts), ammonium salts (e.g., lower alkanolammonium salts and other pharmaceutically acceptable amine salts), for example, methylamine salts, ethylamine salts, propylamine salts, dimethylamine salts, trimethylamine salts, diethylamine salts, triethylamine salts, tert-butylamine salts, ethylenediamine salts, hydroxyethylamine salts, dihydroxyethylamine salts, trihydroxyethylamine salts, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0037] "Pharmaceutically acceptable esters and amides" refer to esters or amides formed by any compound in the structure shown and other compounds that are suitable for use as drugs. Pharmaceutically acceptable esters include organic esters and inorganic esters.

[0038] When the compound represented by Formula I has a carboxyl group, the compound represented by Formula I or its active derivative (e.g., acid chloride, mixed acid anhydride, etc.) can be reacted with the corresponding alcohol (e.g., C1-C6 alcohol, etc.) or its active derivative (e.g., (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl body, (pivaloyloxy)methyl body, benzofuranone body, (isopropoxycarbonyl)oxymethyl body, etc.), or ammonia or the corresponding amine (mono-C1-C6 alkylamine- or di-C1-C6 alkylamine, etc.) according to conventional methods (condensation reaction of carboxylic acids with alcohols or amines); the ester of the compound represented by Formula I can be reacted with the corresponding alcohol (e.g., C1-C6 alcohol, etc.) (ester exchange reaction), or ammonia or the corresponding amine (mono-C1-C6 alkylamine or di-C1-C6 alkylamine, etc.) (amidation reaction). or reacting an alkali metal salt of the compound represented by Formula I with a corresponding halide (e.g., C1-C6 alkyl chloride or bromide, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl chloride or bromide, (pivaloyloxy) methyl chloride or bromide, benzofuranone chloride or bromide, [(isopropoxycarbonyl)oxy] methyl chloride or bromide, etc.) to produce pharmaceutically acceptable esters or amides. Similarly, when the compound represented by Formula I has a hydroxyl group, the compound represented by Formula I can be subjected to a condensation reaction with a carboxylic acid, an acyl chloride, an acid anhydride, etc. according to conventional methods to obtain pharmaceutically acceptable esters.

[0039] The aforementioned esters may be, for example, C1-C6 alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, sec-butyl ester, tert-butyl ester, pentyl ester, and hexyl ester; C3-C6 cycloalkyl esters such as cyclopentyl ester and cyclohexyl ester; C6-C6 cycloalkyl esters such as phenyl ester and naphthyl ester; 10 Aryl esters; benzyl ester, phenylethyl ester, α-methylbenzyl ester, 3-phenylpropyl ester, 4-phenylbutyl ester, 6-phenylhexyl ester, diphenylmethyl ester, triphenylmethyl ester, etc. C6-C 10 Aryl C1-C6 alkyl esters; or esters that can be hydrolyzed in vivo, such as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (pivaloyloxy)methyl ester, benzofuranonyl ester, [(isopropoxycarbonyl)oxy]methyl ester, [(cyclohexyloxycarbonyl)oxy]methyl ester, and 1-[(cyclohexyloxycarbonyl)oxy]ethyl ester.

[0040] The aforementioned amides may be, for example, amide (-CONH2); mono-C1-C6 alkylamides or mono-C3-C6 cycloalkylamides such as N-formamide, N-acetamide, N-propionamide, N-isopropylamide, N-butyramide, N-sec-butyramide, N-tert-butyramide, N-pentanamide, N-hexanamide, N-cyclopropanamide, N-cyclopentanamide, and N-cyclohexanamide; or N,N-diformamide, N,N-diethylamide, N,N-dipropylamide, N-isopropylamide, N-butyramide, N-sec-butyramide, N-tert-butyramide, N-pentanamide, N-hexanamide, N-cyclopropanamide, N-cyclopentanamide, and N-cyclohexanamide; N-C1-C6 alkylamides, N-C1-C6 alkyl-N-C3-C6 cycloalkylamides or di-C3-C6 cycloalkylamides such as amide, N,N-diisopropylamide, N-methyl-N-acetamide, N-methyl-N-propionamide, N-methyl-N-butyramide, N-ethyl-N-propionamide, N-ethyl-N-butyramide, N-butyl-N-cyclopentylamide, N-ethyl-N-cyclopropionamide, N,N-dicyclohexylamide, etc.

[0041] "Solvate" refers to a complex formed by the compound represented by general formula (I) and solvent molecules in a specific ratio. "Hydrate" refers to a complex formed by the compound of the present application and water.

[0042] "Active metabolite" refers to an active derivative of a compound that is formed when the compound is metabolized.

[0043] "Polymorphs" refer to compounds of the present invention that exist in different crystal lattice forms.

[0044] "Isotope-labeled" refers to a compound of the present invention that is isotopically labeled. For example, the isotopes in the compound of the present invention may include various isotopes of elements such as H, C, N, O, P, F, and S, such as 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 S.

[0045] "Isomers" refer to isomers produced by the different spatial arrangements of atoms in a molecule. The compounds of the present application contain structures such as asymmetric or chiral centers, double bonds, etc. Therefore, the compounds of the present application may include multiple isomeric forms such as optical isomers, geometric isomers, tautomers, atropisomers, etc. These isomers and their single isomers, racemates, etc. are all included in the scope of the present application. For example, for optical isomers, optically active (R)- and (S)-isomers and D and L isomers can be prepared by chiral resolution, chiral synthesis or chiral reagents or other conventional techniques. For example, diastereomers can be converted into diastereomers by reaction with appropriate optically active substances (such as chiral alcohols or Mosher's acyl chlorides), which are separated and converted (such as hydrolyzed) into corresponding single isomers. For another example, separation can also be carried out by chromatographic column.

[0046] "Pharmaceutical compositions" may be prepared in a manner well known in the pharmaceutical art and may be administered or applied by a variety of routes depending upon whether local or systemic treatment is desired and upon the area to be treated.

[0047] Administration

[0048] The dosage form and administration method of the compound of the present application or its pharmaceutical composition are not particularly limited.

[0049] Representative routes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular, or subcutaneous) injection, and topical administration.

[0050] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets, and pills, the dosage form may also include a buffer. Solid dosage forms such as tablets, dragees, capsules, pills, and granules may be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may include opacifying agents, and the release of the active compound or compounds in such compositions may be delayed in a certain portion of the digestive tract. Examples of embedding components that may be used are polymeric substances and waxes. If desired, the active compound may also be microencapsulated with one or more of the above-mentioned excipients.

[0051] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers, specifically ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures thereof. In addition to these inert diluents, the composition may also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents, and fragrances. For example, a suspension may contain a suspending agent, specifically ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide, and agar, or mixtures thereof.

[0052] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous or nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0053] Dosage forms for topical administration include ointments, powders, patches, sprays and inhalants, which are prepared by mixing the active ingredient with a pharmaceutically acceptable carrier and any preservatives, buffers, or propellants as necessary under sterile conditions.

[0054] As used herein, "drug" includes any agent, compound, composition, or mixture that provides a physiological and / or pharmacological effect in vivo or in vitro, often with a beneficial effect. The scope of the physiological and / or pharmacological effect produced by the "drug" in vivo is not particularly limited and may be systemic or localized. The activity of the "drug" is not particularly limited and may be an active substance that interacts with other substances or an inert substance that does not interact.

[0055] As used herein, "therapeutically effective amount" refers to the amount of the compound of the present application that will elicit a biological or medical response in an individual, for example, the amount of the compound of the present application that brings about a physiological and / or pharmacologically positive effect in an individual, wherein the physiological and / or pharmacologically positive effect includes but is not limited to reducing or inhibiting enzyme or protein activity or improving symptoms, alleviating symptoms, slowing or delaying disease progression, or preventing disease, etc.

[0056] The TGF-β superfamily is involved in numerous aspects of biology, including embryonic development, organogenesis, cell fate determination, immune regulation, stress responses, and stem cell function. Consequently, extensive research has been conducted on TGF-β, and several TGF-β signaling inhibitors, such as galunisertib (LY2157299), have entered the clinical stage. LY2157299 is a small molecule inhibitor that selectively inhibits the kinase activity of TβRI. It has been studied as a monotherapy or in combination with standard anticancer regimens in patients with various cancers, such as glioblastoma, pancreatic cancer, and hepatocellular carcinoma (Rodon J et al., Clin Cancer Res 2015, 21:553–560). In an initial phase I trial, LY2157299 showed promising activity in patients with glioblastoma. On the other hand, LY2157299 does show advantages over gemcitabine in pancreatic cancer patients (Melisi D et al., Cancer Res 2016, 76(14 Supplement): CT068–CT068). However, existing small molecule inhibitors are still limited in their ability to kill tumor cells and can selectively inhibit a limited number of kinases. Therefore, developing more effective TGF-β signaling inhibitors that can target more kinases to help people treat more diseases, especially cancer, remains an urgent problem to be solved in the medical field.

[0057] Based on the above background, the first aspect of the present application provides a pyrazole carbonyl piperazinone compound having a structure shown in Formula I, or a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled compound, isomer or prodrug of the structure shown in Formula I;

[0058] Wherein, ring A is selected from any of the following structures:

[0059] Y is -(CH2) n -, n is 0, 1, 2 or 3;

[0060] R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1~C6 alkyl, C1~C6 alkoxy, C6~C 10 Aryl or C3~C 10 heteroaryl;

[0061] R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy;

[0062] “*” indicates the attachment site.

[0063] The pyrazolylpiperazinone compounds provided herein, through their unique structural design, can form a relatively stable complex with BMPR1B through hydrogen bonding and hydrophobic interactions, thereby achieving targeted binding with BMPR1B. They can highly selectively inhibit BMPR1B, effectively killing tumor cells and preventing tumor progression and metastasis. Compared to existing small molecule inhibitors, such as LY2157299, the pyrazolylpiperazinone compounds described herein have a higher lethality against tumor cells.

[0064] In some embodiments, Y is -(CH2) n -, n is 0, 1 or 2; preferably, Y is -(CH2) n -, n is 0 or 1; further preferably, Y is -(CH2) n -, n is 0 or 1.

[0065] In some embodiments, R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1~C6 alkyl, C6~C 10 Aryl or C3~C 10 Heteroaryl; preferably, R 1 Selected from -H, -D, unsubstituted or R 2Substituted C3-C6 heteroaryl; further preferably, R 1 Selected from -H, -D, unsubstituted or R 2 substituted furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyran, thiopyran, pyridine, pyridazine or pyrimidine; more preferably, R 1 Selected from -H, -D, or any of the following substituents:

[0066] Wherein, “*” indicates the connection site.

[0067] When R 1 When selected from heteroaryl groups, especially heteroaryl groups substituted with methyl or hydroxyl groups, the formed pyrazolylpiperazinone compounds have higher binding energy with the docking target of BMPR1B and lower physiological toxicity, which is conducive to improving the efficacy and biocompatibility of pyrazolylpiperazinone compounds as BMPR1B inhibitors, making them possible to be used in clinical treatment.

[0068] In some embodiments, R 2 Selected from -OH or C1-C6 alkyl; preferably, R 2 is selected from -OH or C1-C4 alkyl; further preferably, R 2 Selected from -OH, methyl, ethyl, n-propyl or isopropyl.

[0069] In some embodiments, the pyrazole carbonyl piperazinone compound has a structure shown in any one of Formulas I-1 to I-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure shown in any one of Formulas I-1 to I-13;

[0070] In some embodiments, the pyrazole carbonyl piperazinone compound has a structure shown in Formula II, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope label, isomer or prodrug of the structure shown in Formula II;

[0071] Among them, A ring, Y and R 1 As defined in any of the preceding embodiments.

[0072] In some embodiments, the pyrazole carbonyl piperazinone compound has a structure shown in any one of Formulas II-1 to II-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure shown in any one of Formulas II-1 to II-13;

[0073] In a second aspect of the present application, a pharmaceutical composition is provided, comprising the aforementioned pyrazolecarbonylpiperazinone compound and at least one pharmaceutically acceptable carrier.

[0074] The third aspect of the present application provides the use of the aforementioned pyrazole carbonyl piperazinone compound or the aforementioned pharmaceutical composition in the preparation of a medicament for treating one or more of the following diseases: cancer, pulmonary hypertension.

[0075] In some embodiments, the cancer is one or more of ovarian cancer, breast cancer, glioma, and germ cell tumor.

[0076] The fourth aspect of the present application provides the use of the aforementioned pyrazole carbonyl piperazinone compounds as BMPR1B inhibitors.

[0077] In some embodiments, the concentration of the pyrazole piperazinone compound is 10 μM to 100 μM. Alternatively, the concentration of the pyrazole piperazinone compound can be, for example, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM or 90 μM.

[0078] In a fifth aspect of the present application, a method for inhibiting BMPR1B expression is provided, comprising the following steps:

[0079] The pyrazolecarbonylpiperazinone compound described in one or more of the above embodiments is contacted with cells, biological tissues or organoids containing BMPR1B.

[0080] In some embodiments, during the contact treatment, the concentration of the pyrazole piperazinone compound is 10 μM to 100 μM. Alternatively, the concentration of the pyrazole piperazinone compound can be, for example, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, or 90 μM.

[0081] The fifth aspect of the present application provides a method for treating cancer or pulmonary hypertension, comprising the following steps: administering to the patient a therapeutically effective amount of the aforementioned pyrazolecarbonylpiperazinone compound, or administering to the patient a therapeutically effective amount of the aforementioned pharmaceutical composition.

[0082] In some embodiments, the cancer is one or more of ovarian cancer, breast cancer, and glioma.

[0083] Compound synthesis (In the following content, if there is a discrepancy between the compound name and the structural formula, the structural formula shall prevail):

[0084] Synthesis Route A

[0085] Intermediate M1-n (0.12 mmol), (4aS,8aS)-octahydroquinolin-2(1H)-one (M2, 15 mg, 0.1 mmol), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 380 mg, 1 mmol) were mixed. N,N-diisopropylethylamine (DIEA, 2 mL) and N,N-dimethylformamide (DMF, 20 mL) were then added and stirred at room temperature for 18 hours. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane = 3:7) to obtain the desired product II-n.

[0086] Compounds II-1 and II-13 were obtained via synthetic route A:

[0087] II-1:

[0088] (4aS,8aS)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0089] (4aS,8aS)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (12 mg, 41%), LC-MS m / z=289.2 [M+H] + .

[0090] II-13:

[0091] (4aS,8aS)-4-(1H-indazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0092] (4aS,8aS)-4-(1H-indazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (17 mg, 57%), LC-MS m / z=299.2 [M+H] + .

[0093] Synthesis Route B

[0094] Compound II-12 was obtained via synthetic route B:

[0095] II-12:

[0096] (4aS,8aS)-4-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0097] (4aS,8aS)-4-(4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0098] (1) To a solution of 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (M3-1, 0.167 g, 1 mmol) in 2 mL of 1 mol / L NaOH and 0.6 mL of 1,4-dioxane was added dropwise 0.25 g (1.1 mmol) of di-tert-butyl dicarbonate (Boc2O) in 1.5 mL of 1,4-dioxane at 0°C. The reaction mixture was stirred at 0°C for 0.5 h and then reacted at room temperature overnight, maintaining the pH at 8-9. After the reaction, the mixture was diluted with 5 mL of H2O and extracted with n-hexane. The aqueous phase was acidified to pH 2-3 with citric acid and extracted with ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 5-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-3-carboxylic acid (M3-2, 200 mg, 75%), LC-MS m / z = 268.1 [M+H] + ;

[0099] (2) M3-2 (20 mg, 0.075 mmol) was mixed with (4aS,8aS)-octahydroquinolin-2(1H)-one (M2, 15 mg, 0.1 mmol) and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 38 mg, 0.1 mmol). N,N-diisopropylethylamine (DIEA, 0.2 mL) and N,N-dimethylformamide (DMF, 2 mL) were added, and the mixture was stirred at room temperature for 18 hours. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate:hexane=3:7) to give tert-butyl 3-((4aS,8aS)-3-oxodeoxyquinoline-1-carbonyl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxylate (M3-3, 18 mg, 60%), LC-MS m / z=404.2 [M+H] + ;

[0100] (3) M3-3 (18 mg, 0.04 mmol) and trifluoroacetic acid (TFA, 35 mg, 0.3 mmol) were added to 2 mL of dichloromethane (DCM) and stirred at room temperature for half an hour. Ethyl acetate and water were added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure. The obtained product was II-12 (13 mg, 96%), LC-MS m / z = 304.2 [M+H] + .

[0101] Synthetic Route C

[0102] (1) Sodium hydride (60% suspension, 1.07 g, 26.9 mmol) dissolved in tetrahydrofuran (5 mL) was cooled to 0°C, and a solution of M1-n (21.5 mmol) in tetrahydrofuran (50 mL) was added dropwise thereto over 15 minutes, and the mixture was stirred at 0°C for 1 hour. A solution of (2-(chloromethoxy)ethyl)trimethylsilane (M4, 4.76 mL, 26.9 mmol) in tetrahydrofuran (50 mL) was added dropwise to the mixture, and the mixture was stirred at room temperature for 48 hours. Water and ethyl acetate were slowly added to the reaction mixture, the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain M5-n;

[0103] (2) In a 20 mL reactor, R 1 -YX (0.698 mmol, wherein X represents halogen, R 1 and Y are as defined above), (4aS,8aS)-octahydroquinoxalin-2(1H)-one (M2, 108 mg, 0.698 mmol, 1.0 eq.), cesium carbonate (796 mg, 2.443 mmol, 2.5 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 0.035 mmol, 0.05 eq.) and palladium acetate (7.84 mg, 0.035 mmol, 0.05 eq.) were dissolved in tetrahydrofuran (3 mL) and sparged with nitrogen for 10 minutes. The reaction mixture was heated to 70°C and maintained for 90 minutes. The mixture was filtered, washed with dichloromethane, and concentrated. The residue was purified by silica gel column chromatography (0-10% ethyl acetate / dichloromethane) to give M6-n;

[0104] (3) M6-n (1.0 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL), and M5-n (1.2 mmol, 1.2 eq.), triethylamine (200 mg, 2.0 mmol, 2.0 eq.) and tetramethylurea hexafluorophosphate (570 mg, 1.5 mmol, 1.5 eq.) were added to the mixture and stirred overnight. The reaction was monitored by thin layer chromatography. When the reactants were no longer visible, the mixture was diluted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2:1, petroleum ether: ethyl acetate) to obtain M7-n;

[0105] (4) To a solution of M7-n (3.95 mmol) in tetrahydrofuran (39.5 mL) was added triethylsilane (2.30 g, 19.8 mmol) at 5°C and stirred at room temperature for 3 hours. The reaction mixture was concentrated, rinsed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 20-100%) to obtain the desired product II-n.

[0106] Compounds II-2 to II-10 were obtained via synthetic route C:

[0107] II-2:

[0108] (4aS,8aS)-1-(3-methylthiophen-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0109] (4aS,8aS)-1-(3-methylthiophen-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1504 mg, 99%). LC-MS m / z = 384.2 [M+H] + .

[0110] II-3:

[0111] (4aS,8aS)-1-(2-methyloxazol-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0112] (4aS,8aS)-1-(2-methyloxazol-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1445 mg, 99%). LC-MS m / z = 370.2 [M+H] + .

[0113] II-4:

[0114] (4aS,8aS)-1-(3-methylisothiazol-5-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0115] (4aS,8aS)-1-(3-methylisothiazol-5-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1507 mg, 99%). LC-MS m / z = 386.2 [M+H] + .

[0116] II-5:

[0117] (4aS,8aS)-1-(2-methylpyridin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0118] (4aS,8aS)-1-(2-methylpyridin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1469 mg, 98%). LC-MS m / z = 380.2 [M+H] + .

[0119] II-6:

[0120] (4aS,8aS)-1-(6-methylpyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0121] (4aS,8aS)-1-(6-methylpyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1484 mg, 99%). LC-MS m / z = 380.2 [M+H] + .

[0122] II-7:

[0123] (4aS,8aS)-1-(6-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0124] (4aS,8aS)-1-(6-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1491 mg, 99%). LC-MS m / z = 382.2 [M+H] + .

[0125] II-8:

[0126] (4aS,8aS)-1-(4-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0127] (4aS,8aS)-1-(4-hydroxypyridin-2-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1491 mg, 99%). LC-MS m / z = 382.2 [M+H] + .

[0128] II-9:

[0129] (4aS,8aS)-1-(2-methylpyrimidin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0130] (4aS,8aS)-1-(2-methylpyrimidin-4-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1488 mg, 99%). LC-MS m / z = 381.2 [M+H] + .

[0131] II-10:

[0132] (4aS,8aS)-1-(6-methylpyridazin-3-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0133] (4aS,8aS)-1-(6-methylpyridazin-3-yl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (1413 mg, 94%). LC-MS m / z = 381.2 [M+H] + .

[0134] Synthetic Route D

[0135] Compound II-11 was obtained via synthetic route D:

[0136] II-11:

[0137] (4aS,8aS)-1-((5-methyl-1H-pyrazol-4-yl)methyl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0138] (4aS,8aS)-1-((5-methyl-1H-pyrazol-4-yl)methyl)-4-(1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one

[0139] (1) Sodium hydride (60% suspension, 1.07 g, 26.9 mmol) dissolved in tetrahydrofuran (5 mL) was cooled to 0°C, and a solution of 5-methyl-1H-pyrazole-4-carbaldehyde (M8-1, 2.37 g, 21.5 mmol) in tetrahydrofuran (50 mL) was added dropwise over 15 minutes, and the mixture was stirred at 0°C for 1 hour. A solution of (2-(chloromethoxy)ethyl)trimethylsilane (M4, 4.76 mL, 26.9 mmol) in tetrahydrofuran (50 mL) was added dropwise to the mixture, and the mixture was stirred at room temperature for 48 hours. Water and ethyl acetate were slowly added to the reaction mixture, and the organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to give 5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carbaldehyde (M8-2, 4.96 g, 96%). LC-MS m / z=240.1[M+H] + ;

[0140] (2) In a 20 mL reactor, M8-2 (168 mg, 0.698 mmol), (4aS,8aS)-octahydroquinoxalin-2(1H)-one (M2, 108 mg, 0.698 mmol, 1.0 eq.), cesium carbonate (796 mg, 2.443 mmol, 2.5 eq.), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 0.035 mmol, 0.05 eq.), and palladium acetate (7.84 mg, 0.035 mmol, 0.05 eq.) were dissolved in tetrahydrofuran (3 mL) and sparged with nitrogen for 10 minutes. The reaction mixture was heated to 70°C and maintained for 90 minutes. The mixture was filtered, washed with dichloromethane, and concentrated. The residue was purified by silica gel column chromatography (0-10% ethyl acetate / dichloromethane) to give (4aS,8aS)-1-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl)octahydroquinoxalin-2(1H)-one (M8-3, 244 mg, 92.2%). LC-MS m / z = 378.3 [M+H] + ;

[0141] (3) M8-3 (379 mg, 1.0 mmol, 1.0 eq) was dissolved in dichloromethane (10 mL). 1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,6-tetrahydrocyclopentapyrazole-3-carboxylic acid (M8-4, 339 mg, 1.2 mmol, 1.2 eq.), triethylamine (200 mg, 2.0 mmol, 2.0 eq.) and tetramethylurea hexafluorophosphate azobenzotriazole (570 mg, 1.5 mmol, 1.5 eq.) were added to the mixture, and the mixture was stirred overnight. The reaction was monitored by thin layer chromatography. When the reactant was no longer visible, the mixture was diluted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (2:1, petroleum ether:ethyl acetate) to give (4aS,8aS)-1-((5-methyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)methyl)-4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1,4,5,6-tetrahydrocyclopentanopyrazole-3-carbonyl)octahydroquinoxalin-2(1H)-one (M8-5, 424 mg, 66%). LC-MS m / z = 642.4 [M+H] + ;

[0142] (4) Triethylsilane (2.30 g, 19.8 mmol) was added to a solution of M8-5 (2540 mg, 3.95 mmol) in tetrahydrofuran (39.5 mL) at 5°C and stirred at room temperature for 3 hours. The reaction mixture was concentrated, rinsed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate: petroleum ether = 20-100%) to give II-11 (1510 mg, 99%). LC-MS m / z = 383.2 [M+H] + .

[0143] Example 1

[0144] AutoDock Vina software was used to perform molecular docking of the pyrazolylpiperazinone compounds described in this application with the BMPR1B target protein, generating 13 docking conformations. The binding energy of each optimal docking result for the pyrazolylpiperazinone compound and the BMPR1B target protein was calculated. The specific docking results are shown in Table 1. The second column of Table 1 shows the binding free energy calculated by AutoDock Vina molecular docking software. The more negative the value, the stronger the binding ability of the compound to the target protein. The predicted values ​​show that the absolute values ​​of the binding energy values ​​for the pyrazolylpiperazinone compounds are all far greater than the threshold of 3 set based on the target characteristics.

[0145] The cytotoxicity of the pyrazolylpiperazinone compounds in this application was predicted using eToxPred software. The toxicity calculation results of each pyrazolylpiperazinone compound are shown in column 3 of Table 1. The predicted values ​​show that the toxicity of the pyrazolylpiperazinone compounds is less than the threshold value of 0.58 (greater than 0.58 indicates possible toxicity).

[0146] Table 1. Molecular docking binding energy and molecular toxicity prediction of pyrazole-1-piperazinones

[0147] Example 2

[0148] 330 kinase candidates (15-50 nM, 2.5 μL) were mixed with compound II-1 (2.5 mM, 25 nL, prepared in DMSO) and incubated at 25°C for 10 minutes. Then, a mixture of kinase peptide substrate (0.2 mg / mL; supplier: GenScript) and ATP (10-60 μM; supplier: Promega; product number: V915B) (2.5 μL in total, prepared in assay buffer) was added to the mixture, and the mixture was reacted at 25°C for 60-120 minutes. Finally, HTRF was used. 1 or ADP-Glo 2 The reaction products were quantitatively detected. During the kinase activity assay, the consumption of each substrate was less than 10%, and two technical replicates were performed for each kinase activity assay.

[0149] The results showed that II-1 had a significant inhibitory effect on the kinase activity of BMPR1B (Figure 1A; Note: All test results are shown. For ease of reading, the x-axis only shows the name of one kinase for every 10 kinases). However, at the same concentration, II-1 had no inhibitory effect on the kinase activity of TGFBR1 and BMPR2, and at different concentrations (the highest concentration was 12.5 μM, and the concentration was 3-fold serially diluted), there was no inhibitory effect on TGFBR1 and BMPR2 kinases (Figure 1B, C). This result confirms the specific binding ability of II-1 to the target site.

[0150] In order to investigate the above experimental results at the structural level, PyMol software (supplier: ) Structural analysis of the complexes formed by compounds II-1, II-2, II-11, and II-13 with BMPR1B was performed. As shown in Figure 2, the complex structure was obtained by molecular docking. The N- and C-terminal domains of BMPR1B are shown as cartoon models of different shapes, the loop structure of BMPR1 and the loop structure that stimulates catalytic activity (activation loop) are shown as cartoon models of different grayscales, the pyrazolylpiperazinone compounds are shown as stick ring models, the interacting amino acid main chain / side chain are shown as stick models, hydrogen bond interactions are shown as solid lines, and hydrophobic interactions are shown as dotted lines. This result also shows that pyrazolylpiperazinone compounds have structural characteristics that bind to BMPR1B.

[0151] Example 3

[0152] OVCAR3 (ovarian cancer), Hela (breast cancer), U251 (glioma) tumor cells, H9 cells and HEK293 non-tumor cells were cultured in DMEM / F12+10% FBS+1% P / S medium. After the cells reached 70% confluence, they were digested with 0.25% Trypsin digestion solution and digested at 37°C for 2-3 minutes. The digestion was terminated with DMEM / F12. The cell suspension was collected in a 15 mL centrifuge tube, centrifuged at 1000 rpm for 5 minutes, the supernatant was discarded, and the cells were resuspended in DMEM / F12+10% FBS+1% P / S medium and counted on a hemocytometer. According to the counting results, the cells were resuspended in DMEM / F12+10% FBS+1% P / S medium to the corresponding concentration, and 1×10 4 Tumor cells were seeded into 96-well plates at a volume of 100 μL / well. On days 1 to 7 after cell inoculation, cells were treated with compound II-1 at concentrations of 0 μM, 10 μM, 30 μM, and 50 μM (pyrazolylpiperazinone compounds were diluted to 10 μM, 30 μM, and 50 μM in DMEM + 10% FBS medium), with three replicate wells set up for each concentration gradient.

[0153] Cells were selected on days 1, 3, 5, and 7 after treatment and their absorbance at OD450nm was measured using the CCK-8 Cytotoxicity Assay Kit (Vazyme, A311-02). The absorbance values ​​of wells containing only culture medium and the CCK-8 solution served as blank controls. Three replicates were set for each concentration. Cell viability at different time points was calculated based on the absorbance values, as shown in Table 2.

[0154] The cell viability was calculated as follows: For the same cells at the same time point, the absorbance value obtained from cells not treated with Compound II-1 was used as the baseline value (100%). The absorbance values ​​measured after treatment with different concentrations of Compound II-1 were compared with the values ​​of the CK group, and the ratio of the absorbance value to the CK group was calculated. For example, the viability of H9 cells treated with 30 μM of a small molecule compound on day 4 was calculated as follows:

[0155] [OD(D4)30μM iPS] / [OD(D4)0μM H9]×100%

[0156] Table 2 Survival rates of various cells after treatment with different concentrations of compound II-1 as determined by CCK-8

[0157] The results showed that after treating Hela, U251 and OVCAR3 tumor cells with the same concentration of small molecule compound II-1, the cell survival rate showed a gradual downward trend with the extension of time; and as the concentration of compound II-1 increased, the cell viability also showed a downward trend; among them, U251 was more sensitive to small molecule compounds, and its cell survival rate was lower than that of Hela and OVCAR3 cells.

[0158] As an atypical representative of embryonic tumors (such as germ cell tumors), for H9 cells, the survival rate of H9 cells also showed a gradually declining trend with the extension of time and the increase of compound II-1 concentration; however, for non-tumor cells HEK293, the cell survival rate did not show a significant change with the extension of time and the increase of compound II-1 concentration, which indicates that the killing effect of compound II-1 on tumor cells is more specific.

[0159] Example 3

[0160] In this example, compound II-1 and control compound LY2157299 were used to treat glioma cells U251. Samples were taken after 12 hours and 72 hours of induction, and total RNA was extracted using the same target compound using RNeasy Mini or Micro Kit (QIAGEN). 1 mg of RNA was synthesized into cDNA using SuperScript III First-Strand Synthesis System (Invitrogen). SYBR Premix Ex Taq (TaKaRa) and Thermal Cycler Dice Real Time System (TaKaRa) were used for quantitative PCR labeling and reaction, and beta-Actin was used as an internal reference. All data were analyzed using the delta-Ct method. Three groups of experiments were repeated for each test, and variance statistics were performed. The primer sequences for identifying the coding genes of different cell markers are shown in Table 3. The test results are shown in Figure 3. The experiment shows that at the same concentration, compound II-1 shows a higher apoptotic effect than the anti-tumor molecule LY2157299, and fewer cells remain in the compound II-1-treated well plate after 72 hours of treatment. It can be seen that compared with the control compound LY2157299, the pyrazole carbonyl piperazinone compound of the present application has a stronger killing effect on tumor cells.

[0161] Table 3 Primers for cell transcription detection after treatment with compound II-1

[0162] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0163] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent. It should be noted that a person skilled in the art could make several modifications and improvements without departing from the spirit of the present application, all of which fall within the scope of protection of the present application. Therefore, the scope of protection of the patent in this application shall be based on the appended claims, and the specification and drawings may be used to interpret the claims.

Claims

1. A pyrazolecarbonyl piperazinone compound, wherein the pyrazolecarbonyl piperazinone compound has a structure as shown in Formula I, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure as shown in Formula I; in, Ring A is selected from any of the following structures: Y is -(CH2) n -, n is 0, 1, 2 or 3; R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C1-C6 alkoxy, C6-C 10 Aryl or C3~C 10 heteroaryl; R 2 Selected from -F, -Cl, -Br, -I, -OH, -COOH, C1-C6 alkyl or C1-C6 alkoxy; "*" indicates the attachment site.

2. The pyrazole carbonyl piperazinone compound according to claim 1, characterized in that: The pyrazole piperazinone compound meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0, 1 or 2; (2)R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C1-C6 alkyl, C6-C 10 Aryl or C3~C 10 heteroaryl; (3)R 2 Selected from -OH or C1~C6 alkyl.

3. The pyrazole carbonyl piperazinone compound according to claim 2, characterized in that: The pyrazole piperazinone compound meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0 or 1; (2)R 1 Selected from -H, -D, unsubstituted or R 2 Substituted C3-C6 heteroaryl; (3)R 2 Selected from -OH or C1~C4 alkyl.

4. The pyrazole carbonyl piperazinone compound according to claim 3, characterized in that: The pyrazole piperazinone compound meets one or more of the following conditions: (1) Y is -(CH2) n -, n is 0 or 1; (2)R 1 Selected from -H, -D, unsubstituted or R 2 substituted furan, thiophene, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, pyran, thiopyran, pyridine, pyridazine or pyrimidine; (3)R 2 Selected from -OH, methyl, ethyl, n-propyl or isopropyl.

5. The pyrazole carbonyl piperazinone compound according to any one of claims 1 to 4, characterized in that: R 1 Selected from -H, -D or any of the following substituents: Wherein, "*" indicates the connection site.

6. The pyrazole carbonyl piperazinone compound according to any one of claims 1 to 4, characterized in that: The pyrazolecarbonyl piperazinone compound has a structure shown in any one of Formulas I-1 to I-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure shown in any one of Formulas I-1 to I-13; 7. The pyrazole carbonyl piperazinone compound according to any one of claims 1 to 4, characterized in that: The pyrazolecarbonyl piperazinone compound has a structure shown in Formula II, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure shown in Formula II; Among them, ring A, Y and R 1 As defined in any one of claims 1 to 4.

8. The pyrazole carbonyl piperazinone compound according to any one of claims 1 to 4, characterized in that: The pyrazole piperazinone compound has a structure shown in any one of formulas II-1 to II-13, or is a pharmaceutically acceptable salt, ester, amide, solvate, active metabolite, polymorph, isotope-labeled substance, isomer or prodrug of the structure shown in any one of formulas II-1 to II-13; 9. A pharmaceutical composition comprising the pyrazolecarbonylpiperazinone compound according to any one of claims 1 to 8, and at least one pharmaceutically acceptable carrier.

10. Use of the pyrazole carbonyl piperazinone compound according to any one of claims 1 to 8 or the pharmaceutical composition according to claim 9 in the preparation of a medicament for treating one or more of the following diseases: cancer, pulmonary hypertension.

11. The use according to claim 10, characterized in that: The cancer is one or more of ovarian cancer, breast cancer, glioma and germ cell tumor.

12. Use of the pyrazole piperazinone compound according to any one of claims 1 to 8 as a BMPR1B inhibitor.

13. The use according to claim 12, characterized in that: The concentration of the pyrazole carbonyl piperazinone compound is 10 μM to 100 μM.

14. A method for inhibiting BMPR1B expression, comprising the following steps: The pyrazole piperazinone compound according to any one of claims 1 to 8 is contacted with cells, biological tissues or organoids containing BMPR1B.

15. The method according to claim 14, characterized in that When the contact treatment is performed, the concentration of the pyrazole carbonyl piperazinone compound is 10 μM to 100 μM.

16. A method for treating cancer or pulmonary hypertension, comprising the following steps: A therapeutically effective amount of the pyrazolecarbonyl piperazinone compound according to any one of claims 1 to 8 is administered to a patient, or a therapeutically effective amount of the pharmaceutical composition according to claim 9 is administered to a patient.

17. The method according to claim 16, characterized in that The cancer is one or more of ovarian cancer, breast cancer and glioma.

Citation Information

Patent Citations

  • TGF-beta INHIBITORS

    CN107406412A

  • TGF Beta INHIBITOR AND PRODRUGS

    CN113347965A

  • Inhibitors of tgfbeta

    CN1694708A

  • Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment

    US20200239462A1